Market of Drugs for Progressive Dementia with Other Neurological Abnormalities Analyzed in New Research Report

Dallas, TX — (SBWIRE) — 09/28/2012 — The global sales of drugs to treat progressive dementia with other neurological abnormalities expected to reach $537.2 million in 2012 and $913.7 million by 2017, at a CAGR of 11.2% over the five-year forecast period. Sales of drugs to treat Huntington’s disease patients with progressive dementia and other neurological abnormalities expected to reach $354.4 million in 2012 and further increase to $566.8 million in 2017, at a CAGR of 9.8% over the five-year forecast period. The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Extensive research in the field of syndromes of dementia and movement disorders and company collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technological developments are providing disease-modifying therapies for the late stages of the disorders. Collaborations between research institutes and pharmaceutical companies are on the rise as state-of-the-art technology is being explored to develop more efficient products and therapies.

R&D spending, along with increasing competition, patent expiries and new technologies are taking the market in a new direction. Global market revenues increased from 2009 to 2011 and are expected to continue to show growth over the forecast period as new advances, launches and collaborations continue to influence the market. This study looks at most of the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition and changing customer needs.

This study contributes to the areas of market growth in treatments for Alzheimer’s disease, Lewy body dementia, Pick’s disease, Huntington’s disease, corticobasal ganglionic degeneration, Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

Buy your copy of this report @


Source: sbwire

6 Condivisioni